000276086 001__ 276086
000276086 005__ 20240229154956.0
000276086 0247_ $$2doi$$a10.1016/S2352-3026(23)00089-3
000276086 0247_ $$2pmid$$apmid:37187198
000276086 0247_ $$2ISSN$$a2352-3026
000276086 0247_ $$2ISSN$$a2451-9960
000276086 0247_ $$2altmetric$$aaltmetric:148334496
000276086 037__ $$aDKFZ-2023-00992
000276086 041__ $$aEnglish
000276086 082__ $$a610
000276086 1001_ $$aDöhner, Hartmut$$b0
000276086 245__ $$aIntensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
000276086 260__ $$aLondon [u.a.]$$bElsevier$$c2023
000276086 3367_ $$2DRIVER$$aarticle
000276086 3367_ $$2DataCite$$aOutput Types/Journal article
000276086 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1691154882_20939
000276086 3367_ $$2BibTeX$$aARTICLE
000276086 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276086 3367_ $$00$$2EndNote$$aJournal Article
000276086 500__ $$a2023 Jul;10(7):e495-e509
000276086 520__ $$aAcute myeloid leukaemia with mutated NPM1 is associated with high CD33 expression and intermediate-risk cytogenetics. The aim of this study was to evaluate intensive chemotherapy with or without the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in participants with newly diagnosed, NPM1-mutated acute myeloid leukaemia.This open-label, phase 3 trial was conducted at 56 hospitals in Germany and Austria. Eligible participants were 18 years or older and had newly diagnosed NPM1-mutated acute myeloid leukaemia and an Eastern Cooperative Oncology Group performance status of 0-2. Participants were randomly assigned, using age as a stratification factor (18-60 years vs >60 years), 1:1 to the two treatment groups using allocation concealment; there was no masking of participants and investigators to treatment groups. Participants received two cycles of induction therapy (idarubicin, cytarabine, and etoposide) plus all-trans retinoic acid (ATRA) followed by three consolidation cycles of high-dose cytarabine (or an intermediate dose for those older than 60 years) and ATRA, without or with gemtuzumab ozogamicin (3 mg/m2 administered intravenously on day 1 of induction cycles 1 and 2, and consolidation cycle 1). The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population (overall survival was added as a co-primary endpoint after amendment four of the protocol on Oct 13, 2013). The secondary endpoints were event-free survival with long-term follow-up, rates of complete remission, complete remission with partial haematological recovery (CRh), and complete remission with incomplete haematological recovery (CRi), cumulative incidences of relapse and death, and number of days in hospital. This trial is registered with ClinicalTrials.gov (NCT00893399) and has been completed.Between May 12, 2010, and Sept 1, 2017, 600 participants were enrolled, of which 588 (315 women and 273 men) were randomly assigned (296 to the standard group and 292 to the gemtuzumab ozogamicin group). No difference was found in short-term event-free survival (short-term event-free survival at 6-month follow-up, 53% [95% CI 47-59] in the standard group and 58% [53-64] in the gemtuzumab ozogamicin group; hazard ratio [HR] 0·83; 95% CI 0·65-1·04; p=0·10) and overall survival between treatment groups (2-year overall survival, 69% [63-74] in the standard group and 73% [68-78] in the gemtuzumab ozogamicin group; 0·90; 0·70-1·16; p=0·43). There was no difference in complete remission or CRi rates (n=267 [90%] in the standard group vs n=251 [86%] in the gemtuzumab ozogamicin group; odds ratio [OR] 0·67; 95% CI 0·40-1·11; p=0·15) and complete remission or CRh rates (n=214 [72%] vs n=195 [67%]; OR 0·77; 0·54-1·10; p=0·18), whereas the complete remission rate was lower with gemtuzumab ozogamicin (n=172 [58%] vs n=136 [47%]; OR 0·63; 0·45-0·80; p=0·0068). Cumulative incidence of relapse was significantly reduced by gemtuzumab ozogamicin (2-year cumulative incidence of relapse, 37% [95% CI 31-43] in the standard group and 25% [20-30] in the gemtuzumab ozogamicin group; cause-specific HR 0·65; 0·49-0·86; p=0·0028), and there was no difference in the cumulative incidence of death (2-year cumulative incidence of death 6% [4-10] in the standard group and 7% [5-11] in the gemtuzumab ozogamicin group; HR 1·03; 0·59-1·81; p=0·91). There were no differences in the number of days in hospital across all cycles between treatment groups. The most common treatment-related grade 3-4 adverse events were febrile neutropenia (n=135 [47%] in the gemtuzumab ozogamicin group vs n=122 [41%] in the standard group), thrombocytopenia (n=261 [90%] vs n=265 [90%]), pneumonia (n=71 [25%] vs n=64 [22%]), sepsis (n=85 [29%] vs n=73 [25%]). Treatment-related deaths were documented in 25 participants (4%; n=8 [3%] in the standard group and n=17 [6%] in the gemtuzumab ozogamicin group), mostly due to sepsis and infections.The primary endpoints of the trial of event-free survival and overall survival were not met. However, an anti-leukaemic efficacy of gemtuzumab ozogamicin in participants with NPM1-mutated acute myeloid leukaemia is shown by a significantly lower cumulative incidence of relapse rate, suggesting that the addition of gemtuzumab ozogamicin might reduce the need for salvage therapy in these participants. The results from this study provide further evidence that gemtuzumab ozogamicin should be added in the standard of care treatment in adults with NPM1-mutated acute myeloid leukaemia.Pfizer and Amgen.
000276086 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000276086 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276086 7001_ $$aWeber, Daniela$$b1
000276086 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b2
000276086 7001_ $$aFiedler, Walter$$b3
000276086 7001_ $$aKühn, Michael W M$$b4
000276086 7001_ $$aSchroeder, Thomas$$b5
000276086 7001_ $$aMayer, Karin$$b6
000276086 7001_ $$aLübbert, Michael$$b7
000276086 7001_ $$aWattad, Mohammed$$b8
000276086 7001_ $$aGötze, Katharina$$b9
000276086 7001_ $$aFransecky, Lars$$b10
000276086 7001_ $$aKoller, Elisabeth$$b11
000276086 7001_ $$aWulf, Gerald$$b12
000276086 7001_ $$aSchleicher, Jan$$b13
000276086 7001_ $$aRinghoffer, Mark$$b14
000276086 7001_ $$aGreil, Richard$$b15
000276086 7001_ $$aHertenstein, Bernd$$b16
000276086 7001_ $$aKrauter, Jürgen$$b17
000276086 7001_ $$aMartens, Uwe M$$b18
000276086 7001_ $$aNachbaur, David$$b19
000276086 7001_ $$aSamra, Maisun Abu$$b20
000276086 7001_ $$aMachherndl-Spandl, Sigrid$$b21
000276086 7001_ $$aBasara, Nadezda$$b22
000276086 7001_ $$aLeis, Claudia$$b23
000276086 7001_ $$aSchrade, Anika$$b24
000276086 7001_ $$aKapp-Schwoerer, Silke$$b25
000276086 7001_ $$aCocciardi, Sibylle$$b26
000276086 7001_ $$aBullinger, Lars$$b27
000276086 7001_ $$aThol, Felicitas$$b28
000276086 7001_ $$aHeuser, Michael$$b29
000276086 7001_ $$aPaschka, Peter$$b30
000276086 7001_ $$aGaidzik, Verena I$$b31
000276086 7001_ $$aSaadati, Maral$$b32
000276086 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b33
000276086 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard F$$b34$$udkfz
000276086 7001_ $$aDöhner, Konstanze$$b35
000276086 7001_ $$aGanser, Arnold$$b36
000276086 7001_ $$aGroup, German-Austrian AML Study$$b37$$eCollaboration Author
000276086 7001_ $$aDöhner, Hartmut$$b38$$eContributor
000276086 7001_ $$aWeber, Daniela$$b39$$eContributor
000276086 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, Julia$$b40$$eContributor
000276086 7001_ $$aFiedler, Walter$$b41$$eContributor
000276086 7001_ $$aKühn, Michael W M$$b42$$eContributor
000276086 7001_ $$aSchroeder, Thomas$$b43$$eContributor
000276086 7001_ $$aMayer, Karin$$b44$$eContributor
000276086 7001_ $$aLübbert, Michael$$b45$$eContributor
000276086 7001_ $$aWattad, Mohammad$$b46$$eContributor
000276086 7001_ $$aGötze, Katharina$$b47$$eContributor
000276086 7001_ $$aFransecky, Lars$$b48$$eContributor
000276086 7001_ $$aKoller, Elisabeth$$b49$$eContributor
000276086 7001_ $$aWulf, Gerald$$b50$$eContributor
000276086 7001_ $$aSchleicher, Jan$$b51$$eContributor
000276086 7001_ $$aRinghoffer, Mark$$b52$$eContributor
000276086 7001_ $$aGreil, Richard$$b53$$eContributor
000276086 7001_ $$aHertenstein, Bernd$$b54$$eContributor
000276086 7001_ $$aKrauter, Jürgen$$b55$$eContributor
000276086 7001_ $$aMartens, Uwe M$$b56$$eContributor
000276086 7001_ $$aNachbaur, David$$b57$$eContributor
000276086 7001_ $$aSamra, Maisun Abu$$b58$$eContributor
000276086 7001_ $$aMachherndl-Spandl, Sigrid$$b59$$eContributor
000276086 7001_ $$aBasara, Nadezda$$b60$$eContributor
000276086 7001_ $$aLeis, Claudia$$b61$$eContributor
000276086 7001_ $$aSchrade, Anika$$b62$$eContributor
000276086 7001_ $$aKapp-Schwoerer, Silke$$b63$$eContributor
000276086 7001_ $$aCocciardi, Sibylle$$b64$$eContributor
000276086 7001_ $$aBullinger, Lars$$b65$$eContributor
000276086 7001_ $$aThol, Felicitas$$b66$$eContributor
000276086 7001_ $$aHeuser, Michael$$b67$$eContributor
000276086 7001_ $$aPaschka, Peter$$b68$$eContributor
000276086 7001_ $$aGaidzik, Verena I$$b69$$eContributor
000276086 7001_ $$aSaadati, Maral$$b70$$eContributor
000276086 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b71$$eContributor
000276086 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard F$$b72$$eContributor$$udkfz
000276086 7001_ $$aDöhner, Konstanze$$b73$$eContributor
000276086 7001_ $$aGanser, Arnold$$b74$$eContributor
000276086 773__ $$0PERI:(DE-600)2802056-X$$a10.1016/S2352-3026(23)00089-3$$gp. S2352302623000893$$n7$$pe495-e509$$tThe lancet <London> / Haematology$$v10$$x2352-3026$$y2023
000276086 909CO $$ooai:inrepo02.dkfz.de:276086$$pVDB
000276086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000276086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000276086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b34$$kDKFZ
000276086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b40$$kDKFZ
000276086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b71$$kDKFZ
000276086 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b72$$kDKFZ
000276086 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000276086 9141_ $$y2023
000276086 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-19
000276086 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-19
000276086 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET HAEMATOL : 2022$$d2023-08-26
000276086 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000276086 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000276086 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000276086 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000276086 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bLANCET HAEMATOL : 2022$$d2023-08-26
000276086 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000276086 9201_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x1
000276086 980__ $$ajournal
000276086 980__ $$aVDB
000276086 980__ $$aI:(DE-He78)C060-20160331
000276086 980__ $$aI:(DE-He78)W010-20160331
000276086 980__ $$aUNRESTRICTED